Humana leaves AHIP

Humana has terminated its membership in America’s Health Insurance Plans (AHIP), the largest lobbying group for the health insurance industry, following the departures of other major insurers in recent years. 

A Humana spokesperson confirmed to multiple media outlets that the formal termination happened on Dec. 31, but said the company “has not actively participated in AHIP since early 2017.”

AHIP’s clout has already been called into question in recent years after other major insurers left the group. UnitedHealthcare departed in June 2015, followed by Aetna (Humana’s one-time merger partner) announcing in Jan. 2016 it would end its AHIP membership. Its advocacy power had been challenged in 2017 by efforts to repeal and replace the Affordable Care Act—some of which, like the Graham-Cassidy legislation, the group opposed, while others it gave partial praise without fully endorsing the bill.

AHIP spokesperson Kristine Grow said Humana’s departure was “a business decision,” not one based on policy differences or concerns about the direction of the organization.

The organization had added twelve new insurance companies to its membership in 2017: Colorado Access in Aurora, Colo.; Commonwealth Care Alliance in Boston; Community Health Choice in Houston; Medical Card System in Puerto Rico; Neighborhood Health Plan in Smithfield, Rhode Island; Piedmont Community Health Plan in Lynchburg, Virginia; Prominence Health Plan in Reno, Nevada; Security Health Plan in Marshfield, Wisconsin; Sutter Health Plan in Sacramento, California; USAA in San Antonio; VillageCareMAX in New York City; and WellCare Health Plans in Tampa, Florida.

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.